Aroa Biosurgery Limited


Developer, manufacturer and distributor of extracellular-matrix (ECM)–based bioscaffolds and related surgical devices for soft-tissue repair and wound management. Headquartered in Auckland, New Zealand (founded 2008). Maintains regulated quality systems and international regulatory clearances for multiple wound- and reconstruction-focused medical devices and biomaterials.

Industries

Biotechnology
Health Care
Life Science
Manufacturing
Medical Device
Health Care Products Manufacturing
Biotechnology Research

Nr. of Employees

medium (51-250)

Aroa Biosurgery Limited

Mangere, Auckland, New Zealand


Patents

Bioactive agents and methods related thereto

US-12753216-B2

View Details

Fluid drainage or delivery device for treatment site

US-12728192-B2

View Details

Laminated tissue graft product

US-12569326-B2

View Details

Laminated tissue graft product

US-11617639-B2

View Details

Laminated tissue graft product

US-10548705-B2

View Details

Products

Myriad Morcells

Morselized ECM product available in particulate formats for wound and reconstructive applications.

Myriad Morcells Fine

Fine powder/particulate ECM format intended for wound management applications and use in combination with other scaffolds.

Myriad Meshed

Fenestrated/meshed ECM bioscaffold configuration for wound management.

Myriad Matrix

Surgical soft tissue bioscaffold indicated for complex wounds, reconstruction and soft tissue reinforcement.

Symphony

Combination cellular and tissue product comprising an ECM scaffold integrated with hyaluronic acid intended for wound management.

Endoform (restorative bioscaffolds)

ECM restorative bioscaffolds, including natural and antimicrobial variants, for management of acute and chronic wounds.

View All Products

Services

Provision of reimbursement resources, payer coding information and a support contact for clinicians and providers.

Virtual product overview sessions and educational support for clinicians evaluating wound-care and reconstructive products.

Expertise Areas

  • Wound care and soft-tissue repair
  • ECM biomaterials development
  • Composite biomaterial formulation (ECM + biologic excipients)
  • Surgical device development and postoperative management systems
  • Show More (4)

Key Technologies

  • Extracellular matrix (ECM) bioscaffolds
  • Particulate and fine powder ECM formats
  • Meshed/fenestrated ECM sheet configurations
  • Reinforced composite scaffolds combining ECM and structural materials
  • Show More (6)

News & Updates

Audited full year financial results for FY24, including revenue (NZ$69.1M total, NZ$68.0M product revenue), margin and FY25 guidance.

Exclusive agreement to co-promote Endoform in the United States to expand access in post-acute settings; Aroa retains manufacturing and ownership.

Press release summarizing results of a prospective, multicenter randomized controlled trial reporting higher complete wound-closure rates and reduced mean healing time when an ECM–hyaluronic acid composite was added to standard of care for diabetic foot ulcers.

Certified to ISO 13485:2016 and expanded quality management system scope under MDSAP covering the United States, Canada, Australia and Brazil.

Publication of multicentre RCT data demonstrating improved healing outcomes for diabetic foot ulcers when an ECM–HMWHA composite was added to standard of care.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.